Orthofix Medical (NASDAQ:OFIX) Announces Quarterly Earnings Results

Orthofix Medical (NASDAQ:OFIX) issued its quarterly earnings data on Wednesday. The medical device company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.02, FiscalAI reports. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The business had revenue of $210.93 million for the quarter, compared to analysts’ expectations of $209.28 million.

Here are the key takeaways from Orthofix Medical’s conference call:

• Q2 net sales grew 5% on a pro forma constant-currency basis, led by 10% growth in global spine fixation and 11% growth in global limb reconstruction. Biologics stabilized to approximately flat year over year after significant declines in 2025.
• CMS restored Medicare reimbursement for bone-growth stimulators retroactive to May 18, providing an estimated $12 million benefit and improving visibility for Therapeutic Solutions in the second half. The company also launched the redesigned AccelStim 2.0 device.
• Orthofix raised its 2026 outlook to $845 million-$855 million in net sales and $95 million-$98 million in adjusted EBITDA. The increase includes reimbursement recovery and approximately $15 million of European distributor inventory purchases tied to MDR certification work, with most of that revenue expected in Q4.
• Smaller U.S. spine distributors, representing roughly 20% of spine sales, continue to underperform due primarily to weak asset utilization and channel productivity. Management expects the softness to persist through year-end and is considering consolidating or exiting weaker relationships, which implies only about 2%-3% core growth in the second half excluding the European order.
• The company is investing in clinical evidence for biologics products and pursuing a potential diabetic-foot-ulcer indication for its limb-reconstruction technologies. Orthofix also completed initial VIRATA minimally invasive spine cases and expects a full market launch late in the fourth quarter.

Orthofix Medical Price Performance

OFIX stock traded down $1.61 during trading on Wednesday, hitting $10.59. The stock had a trading volume of 857,717 shares, compared to its average volume of 334,068. Orthofix Medical has a twelve month low of $8.85 and a twelve month high of $16.99. The company’s 50-day moving average price is $10.46 and its two-hundred day moving average price is $11.77. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.87 and a quick ratio of 1.76. The stock has a market capitalization of $427.85 million, a P/E ratio of -7.00 and a beta of 0.68.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. TD Cowen restated a “hold” rating on shares of Orthofix Medical in a research report on Thursday, May 21st. Wall Street Zen cut Orthofix Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Stifel Nicolaus cut their price target on Orthofix Medical from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a report on Friday, July 17th. Finally, Barrington Research increased their price target on Orthofix Medical from $15.00 to $17.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $16.00.

Key Orthofix Medical News

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Orthofix reported second-quarter revenue of approximately $210.9 million, exceeding analysts’ $209.3 million estimate. Adjusted earnings were $0.07 per share, ahead of the $0.03-per-share loss expected by Zacks, while the company’s reported GAAP loss of $0.39 per share was slightly better than the $0.41 consensus loss. Orthofix Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company forecast 2026 net sales of $845 million to $855 million, above the roughly $841 million analyst consensus. Management said the outlook is supported in part by a $15 million European MDR inventory order, providing a near-term sales benefit. Orthofix 2026 Net Sales Forecast
• Neutral Sentiment: The earnings call highlighted the revenue outlook and quarterly performance, but the company did not provide a clearly specified full-year EPS forecast in the available guidance update. Orthofix Q2 2026 Earnings Call Summary
• Negative Sentiment: Orthofix remains unprofitable on a GAAP basis, with a negative net margin and negative return on equity. The company is also expected to post a sizable full-year loss, which may outweigh the quarterly earnings and revenue beats for investors seeking evidence of durable profitability. Orthofix Earnings Report

Insider Activity

In other news, insider Aviva Mcpherron sold 3,670 shares of Orthofix Medical stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.38, for a total value of $34,424.60. Following the sale, the insider directly owned 66,330 shares of the company’s stock, valued at $622,175.40. The trade was a 5.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Engine Capital Management, Lp acquired 30,000 shares of Orthofix Medical stock in a transaction that occurred on Thursday, May 7th. The stock was purchased at an average cost of $12.18 per share, with a total value of $365,400.00. Following the completion of the purchase, the insider owned 3,848,573 shares in the company, valued at $46,875,619.14. The trade was a 0.79% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 2.70% of the company’s stock.

Institutional Trading of Orthofix Medical

A number of hedge funds have recently bought and sold shares of the business. VARCOV Co. acquired a new position in shares of Orthofix Medical during the 4th quarter worth approximately $164,000. Engineers Gate Manager LP lifted its position in Orthofix Medical by 92.6% during the fourth quarter. Engineers Gate Manager LP now owns 85,101 shares of the medical device company’s stock worth $1,290,000 after buying an additional 40,923 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in Orthofix Medical during the fourth quarter worth approximately $238,000. AQR Capital Management LLC boosted its stake in Orthofix Medical by 158.3% during the fourth quarter. AQR Capital Management LLC now owns 86,708 shares of the medical device company’s stock worth $1,314,000 after buying an additional 53,144 shares during the last quarter. Finally, Trexquant Investment LP boosted its stake in Orthofix Medical by 216.8% during the fourth quarter. Trexquant Investment LP now owns 136,469 shares of the medical device company’s stock worth $2,069,000 after buying an additional 93,386 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.